APTO-253: Phase Ib hold

Aptose said it received a response from FDA regarding a clinical hold the agency placed last November on its open-label,

Read the full 201 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE